Literature DB >> 22123819

Early alterations of brain cellular energy homeostasis in Huntington disease models.

Fanny Mochel1, Brandon Durant, Xingli Meng, James O'Callaghan, Hua Yu, Emmanuel Brouillet, Vanessa C Wheeler, Sandrine Humbert, Raphael Schiffmann, Alexandra Durr.   

Abstract

Brain energy deficit has been a suggested cause of Huntington disease (HD), but ATP depletion has not reliably been shown in preclinical models, possibly because of the immediate post-mortem changes in cellular energy metabolism. To examine a potential role of a low energy state in HD, we measured, for the first time in a neurodegenerative model, brain levels of high energy phosphates using microwave fixation, which instantaneously inactivates brain enzymatic activities and preserves in vivo levels of analytes. We studied HD transgenic R6/2 mice at ages 4, 8, and 12 weeks. We found significantly increased creatine and phosphocreatine, present as early as 4 weeks for phosphocreatine, preceding motor system deficits and decreased ATP levels in striatum, hippocampus, and frontal cortex of R6/2 mice. ATP and phosphocreatine concentrations were inversely correlated with the number of CAG repeats. Conversely, in mice injected with 3-nitroproprionic acid, an acute model of brain energy deficit, both ATP and phosphocreatine were significantly reduced. Increased creatine and phosphocreatine in R6/2 mice was associated with decreased guanidinoacetate N-methyltransferase and creatine kinase, both at the protein and RNA levels, and increased phosphorylated AMP-dependent protein kinase (pAMPK) over AMPK ratio. In addition, in 4-month-old knock-in Hdh(Q111/+) mice, the earliest metabolic alterations consisted of increased phosphocreatine in the frontal cortex and increased the pAMPK/AMPK ratio. Altogether, this study provides the first direct evidence of chronic alteration in homeostasis of high energy phosphates in HD models in the earliest stages of the disease, indicating possible reduced utilization of the brain phosphocreatine pool.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123819      PMCID: PMC3256882          DOI: 10.1074/jbc.M111.309849

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.

Authors:  Ihn Sik Seong; Elena Ivanova; Jong-Min Lee; Yeun Su Choo; Elisa Fossale; MaryAnne Anderson; James F Gusella; Jason M Laramie; Richard H Myers; Mathieu Lesort; Marcy E MacDonald
Journal:  Hum Mol Genet       Date:  2005-08-22       Impact factor: 6.150

2.  Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.

Authors:  Libin Cui; Hyunkyung Jeong; Fran Borovecki; Christopher N Parkhurst; Naoko Tanese; Dimitri Krainc
Journal:  Cell       Date:  2006-10-06       Impact factor: 41.582

3.  Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy.

Authors:  Ivan Tkac; Janet M Dubinsky; C Dirk Keene; Rolf Gruetter; Walter C Low
Journal:  J Neurochem       Date:  2007-01-08       Impact factor: 5.372

4.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

5.  Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.

Authors:  Andrea Ciarmiello; Milena Cannella; Secondo Lastoria; Maria Simonelli; Luigi Frati; David C Rubinsztein; Ferdinando Squitieri
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

6.  The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases.

Authors:  Andrew D Steele; Walker S Jackson; Oliver D King; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-29       Impact factor: 11.205

7.  Selective defect of in vivo glycolysis in early Huntington's disease striatum.

Authors:  William J Powers; Tom O Videen; Joanne Markham; Lori McGee-Minnich; Joann V Antenor-Dorsey; Tamara Hershey; Joel S Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-13       Impact factor: 11.205

8.  Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin.

Authors:  Tamara Milakovic; Gail V W Johnson
Journal:  J Biol Chem       Date:  2005-06-27       Impact factor: 5.157

9.  Huntingtin interacting proteins are genetic modifiers of neurodegeneration.

Authors:  Linda S Kaltenbach; Eliana Romero; Robert R Becklin; Rakesh Chettier; Russell Bell; Amit Phansalkar; Andrew Strand; Cameron Torcassi; Justin Savage; Anthony Hurlburt; Guang-Ho Cha; Lubna Ukani; Cindy Lou Chepanoske; Yuejun Zhen; Sudhir Sahasrabudhe; James Olson; Cornelia Kurschner; Lisa M Ellerby; John M Peltier; Juan Botas; Robert E Hughes
Journal:  PLoS Genet       Date:  2007-05-11       Impact factor: 5.917

10.  Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.

Authors:  Fanny Mochel; Perrine Charles; François Seguin; Julie Barritault; Christiane Coussieu; Laurence Perin; Yves Le Bouc; Christiane Gervais; Guislaine Carcelain; Anne Vassault; Josué Feingold; Daniel Rabier; Alexandra Durr
Journal:  PLoS One       Date:  2007-07-25       Impact factor: 3.240

View more
  55 in total

Review 1.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

2.  Gender differences in the effect of tobacco use on brain phosphocreatine levels in methamphetamine-dependent subjects.

Authors:  Young-Hoon Sung; Deborah A Yurgelun-Todd; Douglas G Kondo; Xian-Feng Shi; Kelly J Lundberg; Tracy L Hellem; Rebekah S Huber; Erin C McGlade; Eun-Kee Jeong; Perry F Renshaw
Journal:  Am J Drug Alcohol Abuse       Date:  2015-04-14       Impact factor: 3.829

3.  Inositol hexakisphosphate kinase-2 determines cellular energy dynamics by regulating creatine kinase-B.

Authors:  Latika Nagpal; Michael D Kornberg; Lauren K Albacarys; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

4.  Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy.

Authors:  Isaac M Adanyeguh; Marie-Lorraine Monin; Daisy Rinaldi; Léorah Freeman; Alexandra Durr; Stéphane Lehéricy; Pierre-Gilles Henry; Fanny Mochel
Journal:  NMR Biomed       Date:  2018-01-09       Impact factor: 4.044

5.  Neuroprotective Effect of Creatine and Pyruvate on Enzyme Activities of Phosphoryl Transfer Network and Oxidative Stress Alterations Caused by Leucine Administration in Wistar Rats.

Authors:  Elenara Rieger; Itiane Diehl de Franceschi; Thales Preissler; Clovis Milton Duval Wannmacher
Journal:  Neurotox Res       Date:  2017-06-13       Impact factor: 3.911

6.  Triheptanoin improves brain energy metabolism in patients with Huntington disease.

Authors:  Isaac Mawusi Adanyeguh; Daisy Rinaldi; Pierre-Gilles Henry; Samantha Caillet; Romain Valabregue; Alexandra Durr; Fanny Mochel
Journal:  Neurology       Date:  2015-01-07       Impact factor: 9.910

7.  A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease.

Authors:  Andrew M Tidball; Miles R Bryan; Michael A Uhouse; Kevin K Kumar; Asad A Aboud; Jack E Feist; Kevin C Ess; M Diana Neely; Michael Aschner; Aaron B Bowman
Journal:  Hum Mol Genet       Date:  2014-12-08       Impact factor: 6.150

Review 8.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

9.  Oxygen consumption deficit in Huntington disease mouse brain under metabolic stress.

Authors:  Song Lou; Victoria C Lepak; Lynn E Eberly; Brian Roth; Weina Cui; Xiao-Hong Zhu; Gülin Öz; Janet M Dubinsky
Journal:  Hum Mol Genet       Date:  2016-05-18       Impact factor: 6.150

10.  A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington's disease: looking for biomarkers.

Authors:  Jolanta Krzysztoń-Russjan; Daniel Zielonka; Joanna Jackiewicz; Sylwia Kuśmirek; Irena Bubko; Aneta Klimberg; Jerzy T Marcinkowski; Elżbieta L Anuszewska
Journal:  J Bioenerg Biomembr       Date:  2012-10-16       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.